Skip to content

Psilocybin for addiction: all studies

Page 12 of 19: studies 111 to 120 of 183, newest first. Back to the psilocybin for addiction overview

Research

Psychedelics in the Treatment of Substance Use Disorders

Psychiatric Annals September 1, 2022 Brian S. Barnett, Jeremy Weleff 6 citations

Growing evidence from observational studies and clinical trials suggests that psychedelics such as lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, and psilocybin may hold treatment potential for alcohol, opioid, tobacco, and other substance use disorders (SUDs). The mechanisms by which psychedelics might exert therapeutic efficacy in these conditions have not been fully...

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

JAMA Psychiatry August 24, 2022 Michael P. Bogenschutz, Stephen Ross, Snehal Bhatt et al. 668 citations

Importance Although classic psychedelic medications have shown promise in the treatment of alcohol use disorder (AUD), the efficacy of psilocybin remains unknown. Objective To evaluate whether 2 administrations of high-dose psilocybin improve the percentage of heavy drinking days in patients with AUD undergoing psychotherapy relative to outcomes observed with active placebo medication and...

Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder

Journal of Psychedelic Studies August 5, 2022 John Clifton, Annabelle M. Belcher, Aaron D. Greenblatt et al. 6 citations

Abstract Background and aims There is growing evidence that psilocybin, a serotonergic psychedelic substance, may be useful in the treatment of substance use disorders. However, there is a lack of data on the beliefs and attitudes towards psilocybin amongst Black individuals diagnosed with Opioid Use Disorder (OUD). This study characterized psilocybin use patterns and perception of risk amongst...

Possible Therapeutics Effects of Ayahuasca, a Psychedelic Compound

European Psychiatry June 1, 2022 L. Silva, L. Bravo

Introduction Ayahuasca is an hallucinogenic tea prepared from the Amazonian vine Banisteriopsis caapi and the leaves of the plant Psychotria Viridis. Banisteriopsis caapi contains monoamine oxidase inhibitors (MAO) that render the N, N-dimethyltryptamine (DMT) of Psychotria Viridis active. This brew is being used as a sacrament in syncretic religions in urban areas of Brazil and worldwide with...

Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin

SURG Journal June 1, 2022 Anthony Principe 1 citation

This review presents a general background of psilocybin pharmacology and discusses its uses in treating various mental health disorders such as depression, anxiety, obsessive-compulsive disorder, and addiction. A summary of preliminary clinical trials utilizing psilocybin in each disorder is presented, along with an analysis of the neurobiological mechanisms that could explain the results. The...

Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders

Molecules April 13, 2022 Henry Lowe, Ngeh J. Toyang, Blair Steele et al. 53 citations

The word “psychedelic” (psyche (i.e., the mind or soul) and delos (i.e., to show)) has Greek origin and was first coined by psychiatrist Humphry Osmond in 1956, who had been conducting research on lysergic acid diethylamide (LSD) at the time. Psychedelic drugs such as N,N-DMT/DMT (N,N-dimethyltryptamine), 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), LSD (lysergic acid diethylamide), MDMA...

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample

Scientific Reports April 7, 2022 Grant Jones, Jocelyn A. Ricard, Joshua Lipson et al. 56 citations

Abstract Opioid use disorder (OUD) is a major source of morbidity and mortality in the U.S. and there is a pressing need to identify additional treatments for the disorder. Classic psychedelics (psilocybin, peyote, mescaline, LSD) have been linked to the alleviation of various substance use disorders and may hold promise as potential treatments for OUD. The aim of this study was to assess...

Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain

Journal of Fungi March 11, 2022 Elaine Meade, Sarah Hehir, Neil J. Rowan et al. 24 citations

Mushrooms have been used as traditional medicine for millennia, fungi are the main natural source of psychedelic compounds. There is now increasing interest in using fungal active compounds such as psychedelics for alleviating symptoms of mental health disorders including major depressive disorder, anxiety, and addiction. The anxiolytic, antidepressant and anti-addictive effect of these...

Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?

Journal of Xenobiotics February 7, 2022 Maurizio Coppola, Francesco Bevione, Raffaella Mondola 29 citations

Psychedelics extracted from plants have been used in religious, spiritual, and mystic practices for millennia. In 1957, Dr. Hofmann identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although there were limitations related to the scientific design of many studies, clinical observations performed during the 1950s and 1960s...

Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review

Cureus February 5, 2022 Shawn Ziff, Benjamin Stern, Gregory D. Lewis et al. 32 citations

Psilocybin-containing mushrooms have been consumed by various cultures in many different parts of the world for thousands of years. Psilocybin, a classic psychedelic, contains unique psychoactive properties and has been incorporated into religious ceremonies and investigated for its medicinal value. In the mid-20th century, psilocybin, along with most other classic psychedelics (5HT-2A...